GSK Set To Begin Trials On Japan’s Third Bird-Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry gave GlaxoSmithKline fast-track status for its bird-flu vaccine, clearing the way for clinical trials to begin as early as this year. If successful, the GSK pre-pandemic vaccine against the H5N1 flu virus would be the third approved for marketing in Japan, which already has stockpiled enough doses for 20 million people. GSK has approval for its vaccine in the European Union. The medical community would like to have as many choices of vaccines as possible because of uncertainties surrounding a possible pandemic of the virus. (Click here for more - a subscription may be required
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.